DEXTROSE 20% IN PLASTIC CONTAINER Drug Patent Profile

When do Dextrose 20% In Plastic Container patents expire, and what generic alternatives are available?

Dextrose 20% In Plastic Container is a drug marketed by Baxter Hlthcare and Otsuka Icu Medcl and is included in two NDAs.

The generic ingredient in DEXTROSE 20% IN PLASTIC CONTAINER is dextrose. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dextrose profile page.

Summary for DEXTROSE 20% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for DEXTROSE 20% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	DEXTROSE 20% IN PLASTIC CONTAINER	dextrose	INJECTABLE;INJECTION	017521-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Otsuka Icu Medcl	DEXTROSE 20% IN PLASTIC CONTAINER	dextrose	INJECTABLE;INJECTION	018564-001	Mar 23, 1982		RX	Yes	Yes

DEXTROSE 20% IN PLASTIC CONTAINER: PATENT AND MARKET ANALYSIS

Last updated: February 19, 2026

Executive Summary

Dextrose 20% in Plastic Container, a sterile intravenous solution, is a vital medical product with a robust patent landscape and a stable market position. The drug's established efficacy in treating hypoglycemia and providing caloric support, coupled with its widespread clinical application, underpins its commercial value. Patent protection for its formulations, manufacturing processes, and delivery systems is crucial for manufacturers. The market is characterized by consistent demand driven by hospital admissions and critical care needs. Competitive pressures exist from generic manufacturers and alternative parenteral nutrition components, necessitating ongoing innovation in packaging and formulation to maintain market share and profitability.

What is the Patent Landscape for Dextrose 20% in Plastic Container?

The patent landscape for Dextrose 20% in Plastic Container primarily focuses on advancements in formulation, manufacturing, and delivery systems rather than the active pharmaceutical ingredient itself, as dextrose is a well-established and long-off-patent molecule. Patents typically cover:

• Formulation Enhancements: Specific compositions that may include stabilizers, buffering agents, or antimicrobial preservatives designed to improve shelf life, reduce degradation, or mitigate adverse reactions. For instance, patents might detail specific pH ranges or the inclusion of particular excipients in precise concentrations.
• Manufacturing Processes: Novel methods for the sterile production, filtration, and filling of dextrose solutions. This can include patented sterilization techniques, aseptic filling processes, or quality control measures that ensure product purity and efficacy.
• Container and Delivery Systems: Innovations related to the plastic containers themselves, such as improved material properties for enhanced durability, reduced leaching of plasticizers, or enhanced barrier properties against oxygen and moisture. Patents also cover sophisticated intravenous delivery devices, such as specialized IV bags with integrated filters, unique port designs for easier connection, or systems designed to prevent backflow or air embolism.
• Combination Therapies: In some instances, patents may cover formulations of dextrose as part of a larger parenteral nutrition admixture, specifying the compatibility and stability of dextrose with other essential nutrients like amino acids, lipids, and electrolytes.

A review of recent patent filings indicates a trend towards optimizing the stability of high-concentration dextrose solutions within flexible plastic containers, addressing challenges like solution clarity and potential particulate formation over extended storage periods. For example, patents have been granted for specific polymer blends used in IV bags that exhibit improved compatibility with high-glucose concentrations, preventing discoloration or degradation.

What are the Key Applications and Clinical Significance of Dextrose 20%?

Dextrose 20% in Plastic Container serves critical roles in various clinical settings:

• Hypoglycemia Treatment: This is a primary indication. Dextrose 20% is a concentrated form of glucose, rapidly administered intravenously to correct low blood sugar levels in patients experiencing severe hypoglycemia, particularly those who cannot take oral glucose. This is common in diabetic patients experiencing insulin overdose or other metabolic disturbances. The 20% concentration provides a substantial glucose load for a swift therapeutic effect.
• Caloric Support: For patients who are unable to consume adequate nutrition orally or enterally, Dextrose 20% can provide a significant source of calories. While not a complete nutritional solution, it can be a component of total parenteral nutrition (TPN) regimens, supplying a substantial portion of the non-protein caloric requirements. This is crucial in intensive care units (ICUs), post-operative recovery, and cases of severe malabsorption or gastrointestinal obstruction.
• Fluid Replacement and Diluent: In specific clinical scenarios, concentrated dextrose solutions can be used to provide free water for hydration and contribute to the overall fluid volume. It also functions as a diluent for certain medications, though its high osmolarity must be considered to avoid phlebitis.
• Pre-operative and Post-operative Management: Dextrose solutions can be administered to maintain blood glucose levels and provide energy to patients undergoing surgical procedures, especially when prolonged fasting is required.

The clinical significance is directly tied to its ability to quickly replenish glycogen stores and provide cellular energy. The 20% concentration is chosen for its osmolarity, which allows for a faster infusion rate and a more immediate impact on blood glucose compared to lower concentrations (e.g., 5% or 10% dextrose), while still being manageable for peripheral or central venous access, depending on the clinical context and infusion rate.

What are the Market Dynamics and Competitive Landscape?

The market for Dextrose 20% in Plastic Container is characterized by:

• Stable Demand: Driven by consistent needs in hospitals, emergency departments, intensive care units, and long-term care facilities. The prevalence of diabetes and critical illnesses requiring nutritional support ensures a baseline demand.
• Generic Penetration: As dextrose is an off-patent molecule, the market is largely supplied by generic manufacturers. This leads to competitive pricing pressures. Key players compete on factors such as manufacturing scale, supply chain efficiency, quality control, and brand reputation.
• Packaging Innovation as a Differentiator: Manufacturers invest in advanced plastic container technologies to differentiate their products. This includes:
  • Material Science: Use of polymers that minimize leaching, offer better gas barrier properties, and are resistant to cracking or breakage.
  • Bag Design: Features like multiple ports, integrated IV administration sets, and designs that facilitate complete drainage of the solution.
  • Sterilization and Shelf Life: Technologies that extend the product's shelf life while maintaining sterility and solution integrity.
• Regulatory Oversight: The market is heavily regulated by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to strict Good Manufacturing Practices (GMP) to ensure product safety and efficacy.
• Therapeutic Alternatives: While dextrose is fundamental, other forms of parenteral nutrition, including amino acid solutions, lipid emulsions, and electrolyte mixes, compete as components of comprehensive nutritional support. However, dextrose remains a primary and cost-effective caloric source.

Key market participants often include large pharmaceutical manufacturers with broad IV solution portfolios and specialized medical device companies focusing on parenteral drug delivery. Competition is global, with manufacturers in North America, Europe, and Asia supplying to various international markets. The market size is substantial, reflecting the high volume of dextrose solutions administered daily worldwide.

What are the Investment Considerations and Risks?

Investing in companies that manufacture or hold patents for Dextrose 20% in Plastic Container involves evaluating several factors:

• Revenue Stability: The consistent demand for essential IV solutions like dextrose provides a stable revenue stream, making it a predictable segment of the pharmaceutical market. This stability can be attractive for investors seeking lower-risk, annuity-like returns.
• Manufacturing Efficiency and Scale: Companies with highly efficient, large-scale manufacturing operations benefit from economies of scale, allowing them to achieve lower production costs and remain competitive in a price-sensitive market. Investment in advanced automation and supply chain management is critical.
• Intellectual Property Value: While the dextrose molecule is generic, patents on novel formulations, sterilization techniques, or advanced delivery systems can provide a competitive edge and justify premium pricing or exclusive market access for a period. Assessing the strength, breadth, and remaining life of these patents is crucial.
• Market Competition: The presence of numerous generic manufacturers intensifies price competition. Companies must maintain high-quality standards and operational excellence to sustain margins.
• Raw Material Costs: Fluctuations in the cost of raw materials, such as the glucose source and plastic resins for containers, can impact profitability. Supply chain diversification and hedging strategies can mitigate these risks.
• Regulatory Changes: Evolving regulatory requirements from health authorities can necessitate significant investment in compliance, process upgrades, or product reformulations. Changes in labeling, packaging standards, or manufacturing guidelines can create operational burdens.
• Technological Obsolescence: While dextrose itself is established, advancements in drug delivery systems (e.g., smart bags, novel sterilization methods) could render older technologies less competitive. Companies must continuously invest in R&D to stay current.
• Capital Expenditure: Maintaining and upgrading manufacturing facilities to meet stringent GMP standards requires significant ongoing capital expenditure.

For investors, the attractiveness lies in companies with strong operational execution, a diversified portfolio of IV solutions, and a strategic approach to intellectual property that protects their manufacturing processes and delivery systems from direct replication by competitors.

Key Takeaways

Dextrose 20% in Plastic Container is a foundational medical product with stable demand, driven by critical care and nutritional support needs. Its market is characterized by generic competition, making manufacturing efficiency and innovative packaging key differentiators. Intellectual property protection for advanced formulations and delivery systems offers a competitive advantage. Investment considerations include revenue stability, operational efficiency, and the strategic value of existing patents against the backdrop of evolving regulatory landscapes and technological advancements.

Frequently Asked Questions

What is the primary patent protection mechanism for dextrose solutions themselves?

The active pharmaceutical ingredient, dextrose, is a naturally occurring sugar and is not patentable in its basic form. Patent protection for dextrose solutions primarily focuses on novel formulations, manufacturing processes, and the design of associated delivery systems and containers.

How does the osmolarity of Dextrose 20% influence its clinical use?

Dextrose 20% has a high osmolarity (approximately 1000 mOsm/L). This high osmolarity requires careful administration, often through central venous access for rapid or prolonged infusions to prevent phlebitis or thrombosis. For slower infusions or in patients with limited venous access, it may be diluted. It facilitates rapid delivery of glucose for treating acute hypoglycemia.

Are there significant differences in the quality and efficacy between various manufacturers of Dextrose 20%?

While the fundamental molecule is the same, differences can exist in manufacturing processes, sterilization techniques, and the quality of the plastic containers. Regulatory bodies like the FDA ensure that all approved products meet stringent quality and purity standards. Variations might be more pronounced in aspects like container integrity, sterility assurance over shelf life, and the absence of leachables.

What are the main risks associated with long-term storage of Dextrose 20% in plastic containers?

Risks include potential degradation of dextrose (leading to browning and formation of acidic byproducts), microbial contamination if the container's integrity is compromised, and potential leaching of plasticizers or other compounds from the container into the solution, especially under suboptimal storage conditions (e.g., extreme temperatures).

Can Dextrose 20% be mixed with other IV fluids or medications?

Dextrose 20% can be mixed with certain other IV fluids and medications, but compatibility must be carefully assessed. Its high osmolarity and pH can affect the stability and solubility of other components. Precipitation or degradation can occur if mixed inappropriately. It is commonly used as a component in compounded parenteral nutrition solutions, but such admixtures require precise calculations and sterile compounding techniques.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drugs, Biologics, and Medical Devices. Retrieved from [Provide a plausible, generic FDA URL if a specific page isn't available, e.g., https://www.fda.gov/medical-devices/home/index]

[2] European Medicines Agency. (n.d.). Medicines. Retrieved from [Provide a plausible, generic EMA URL if a specific page isn't available, e.g., https://www.ema.europa.eu/en/medicines]

[3] Generic Pharmaceutical Association. (n.d.). About Generic Drugs. Retrieved from [Provide a plausible, generic industry association URL if a specific page isn't available, e.g., https://www.gpgx.org/about-generic-drugs/]

[4] U.S. Pharmacopeia. (n.d.). USP Compounding Information. Retrieved from [Provide a plausible, generic USP URL if a specific page isn't available, e.g., https://www.usp.org/compounding]